Washington: 250 million honeybees escape overturned truck in US
An estimated 250 million bees escaped from an overturned truck in the US state of Washington on Friday, sparking warnings from authorities for the public to avoid the swarm of stinging insects.Emergency officials were helped by several master bee-keepers after the truck, which had been hauling roughly 70,000 lb (31,750 kg) of active honey bee hives, flipped over on a road near the Canadian border."The goal is to save as many bees as possible," Whatcom County Sheriff's Office (WCSO) said shortly after the incident.The authorities said the site of the crash would remain closed "until the rescue is complete".
"250 million bees are now loose," wrote Whatcom County Sheriff. "AVOID THE AREA due to the potential of bee escaping and swarming".Bee-keepers worked with police "to assist in re-setting the box hives", containers bee-keepers use to house honeybees. "The plan is to allow the bees to re-hive and find their queen bee," WCSO said, adding: "That should occur within the next 24-48 hours."In an update posted to social media later on Friday, police thanked "the wonderful community of bee-keepers", saying "over two dozen" had turned up to help with the rescue efforts."By morning, most bees should have returned to their hives," WCSO wrote on Facebook.Footage shared by police showed huge numbers of bees swarming around the overturned lorry.While some bee-keepers aim only to produce honey, many others rent out their hives to farmers who need the insects to pollinate their crops.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
27 minutes ago
- Reuters
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
CHICAGO, June 1 (Reuters) - Treating breast cancer patients with AstraZeneca's (AZN.L), opens new tab experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding that could change the way such cancers are treated, cancer experts said on Sunday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in the risk of disease progression or death, said Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky believes the data will likely result in a new treatment paradigm. The trial involved 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as estrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' (NOVN.S), opens new tab Kisqali, Pfizer's (PFE.N), opens new tab Ibrance or Lilly's (LLY.N), opens new tab Verzenio, which block an enzyme that fuels cancer growth. About 40% of patients treated with aromatase inhibitors develop mutations in the estrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called Selective Estrogen Receptor Degraders (SERDS) block estrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to look for ESR1 mutations until 315 patients were identified. They were randomly assigned to either switch to camizestrant plus the CDK4/6 inhibitor (157 patients) or continue with standard treatment plus a placebo (158 patients). The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr. Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Separately, adding AstraZeneca's immunotherapy durvalumab to standard treatment before and after surgery in patients with early-stage stomach and esophageal cancers helped extend the time patients had without cancer progression or recurrence compared to chemotherapy alone. The global study of nearly 950 patients tested durvalumab, sold under the brand Imfinzi, in combination with a chemotherapy regimen called FLOT given around the time of initial cancer surgery. Patients in the durvalumab plus FLOT arm experienced a 29% better event-free survival than those who received the chemotherapy regimen. "We demonstrate that immunotherapy works in early-stage disease, which is great," lead study author Dr. Yelena Jarnigan of Memorial Sloan Kettering Cancer Center in New York told reporters at the meeting. "We did not see any new safety signals, so this will change practice for our patients, which is exciting to see." Both studies were published on Sunday in the New England Journal of Medicine.
The Independent
29 minutes ago
- The Independent
Exercise boosts survival rates in colon cancer patients, study shows
A three-year exercise program improved survival in colon cancer patients and kept disease at bay, a first-of-its-kind international experiment showed. With the benefits rivaling some drugs, experts said cancer centers and insurance plans should consider making exercise coaching a new standard of care for colon cancer survivors. Until then, patients can increase their physical activity after treatment, knowing they are doing their part to prevent cancer from coming back. 'It's an extremely exciting study,' said Dr. Jeffrey Meyerhardt of Dana-Farber Cancer Institute, who wasn't involved in the research. It's the first randomized controlled trial to show how exercise can help cancer survivors, Meyerhardt said. Prior evidence was based on comparing active people with sedentary people, a type of study that can't prove cause and effect. The new study — conducted in Canada, Australia, the United Kingdom, Israel and the United States — compared people who were randomly selected for an exercise program with those who instead received an educational booklet. 'This is about as high a quality of evidence as you can get,' said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology. 'I love this study because it's something I've been promoting but with less strong evidence for a long time.' The findings were featured Sunday at ASCO's annual meeting in Chicago and published by the New England Journal of Medicine. Academic research groups in Canada, Australia and the U.K. funded the work. Researchers followed 889 patients with treatable colon cancer who had completed chemotherapy. Half were given information promoting fitness and nutrition. The others worked with a coach, meeting every two weeks for a year, then monthly for the next two years. Coaches helped participants find ways to increase their physical activity. Many people, including Terri Swain-Collins, chose to walk for about 45 minutes several times a week. 'This is something I could do for myself to make me feel better,' said Swain-Collins, 62, of Kingston, Ontario. Regular contact with a friendly coach kept her motivated and accountable, she said. 'I wouldn't want to go there and say, 'I didn't do anything,' so I was always doing stuff and making sure I got it done.' After eight years, the people in the structured exercise program not only became more active than those in the control group but also had 28% fewer cancers and 37% fewer deaths from any cause. There were more muscle strains and other similar problems in the exercise group. 'When we saw the results, we were just astounded,' said study co-author Dr. Christopher Booth, a cancer doctor at Kingston Health Sciences Centre in Kingston, Ontario. Exercise programs can be offered for several thousand dollars per patient, Booth said, 'a remarkably affordable intervention that will make people feel better, have fewer cancer recurrences and help them live longer.' Researchers collected blood from participants and will look for clues tying exercise to cancer prevention, whether through insulin processing or building up the immune system or something else. Swain-Collins' coaching program ended, but she is still exercising. She listens to music while she walks in the countryside near her home. That kind of behavior change can be achieved when people believe in the benefits, when they find ways to make it fun and when there's a social component, said paper co-author Kerry Courneya, who studies exercise and cancer at the University of Alberta. The new evidence will give cancer patients a reason to stay motivated. 'Now we can say definitively exercise causes improvements in survival,' Courneya said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Reuters
32 minutes ago
- Reuters
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published in Nature Medicine, is the latest among several efforts testing next-generation chimeric antigen receptor T-cell or CAR-T treatments, a type of immunotherapy in which patients' immune cells are engineered to recognize and kill cancer cells. The work, from researchers at the University of Pennsylvania and Gilead's (GILD.O), opens new tab Kite cell therapy unit, tested a dual CAR-T treatment in an effort to overcome the defenses of glioblastoma, the most common brain tumor in adults. CAR-T therapy is already used to treat blood cancers including leukemia, lymphoma and multiple myeloma, and those treatments typically only take aim at one target on the tumor. But solid tumors such as glioblastoma tend to have multiple subpopulations of tumor cells, suggesting that treatments will need more than one target to succeed, said University of Pennsylvania researcher Dr. Stephen Bagley, who led the study. For the treatment, which is injected directly into spinal fluid, the team selected EGFR, which is found in 50% to 60% of all glioblastoma tumors, and a second target called interleukin-13 receptor alpha 2, found in an estimated 75% of glioblastoma tumors. Typically, advanced glioblastoma patients whose cancers return after initial treatment with surgery, radiation and chemotherapy live six to 10 months. Interim results of just six patients were published in March 2024 in Nature Medicine, opens new tab. The current study now includes 18 patients treated with the experimental therapy after their tumors returned following standard treatment. Of these, only 13 had a measurable tumor at the time the cells were introduced, and of those, eight, or 62%, had their tumors shrink, Bagley said. "That was pretty remarkable to us because historically for recurrent glioblastoma tumors, we usually don't see anything shrink them." Several patients lived 12 months or longer, and in one patient, the disease remained stable for 16 months. But so far, the benefit is largely temporary, with many patients relapsing two to three months later. Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was persistence," she said. Kite is working to develop a third target that will allow the drug to remain in the brain longer. "We will be putting that construct into the clinic sometime next year," she said. Meanwhile, the team wants to test the therapy in 12 patients with newly diagnosed disease. "We know patients in the frontline setting are going to be healthier," she said, and the hope is to see more persistent results. Demand for the trial has been great. Perettie estimates there are 10 times as many patients seeking enrollment for every open slot, and some doctors are referring patients from as far away as Hawaii. "Today, there's only one approved therapy outside of radiation, so for these patients, this is really exciting to see any kind of response," she said. Kite hopes to expand to three or four centers with its triple-target version of the product. "I think we're on the right track," Bagley said, adding that he believes there will be longer-lasting treatments in the next few years.
